- Home
- CCTG vs BCDA Comparison
CCTG vs BCDA Comparison
Compare CCTG & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCTG
- BCDA
- Stock Information
- Founded
- CCTG 1993
- BCDA N/A
- Country
- CCTG Hong Kong
- BCDA United States
- Employees
- CCTG N/A
- BCDA N/A
- Industry
- CCTG
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- CCTG
- BCDA Health Care
- Exchange
- CCTG Nasdaq
- BCDA Nasdaq
- Market Cap
- CCTG 12.5M
- BCDA 10.1M
- IPO Year
- CCTG 2024
- BCDA N/A
- Fundamental
- Price
- CCTG $1.05
- BCDA $2.30
- Analyst Decision
- CCTG
- BCDA Strong Buy
- Analyst Count
- CCTG 0
- BCDA 1
- Target Price
- CCTG N/A
- BCDA $25.00
- AVG Volume (30 Days)
- CCTG 4.7K
- BCDA 246.6K
- Earning Date
- CCTG 08-23-2025
- BCDA 08-12-2025
- Dividend Yield
- CCTG N/A
- BCDA N/A
- EPS Growth
- CCTG N/A
- BCDA N/A
- EPS
- CCTG N/A
- BCDA N/A
- Revenue
- CCTG $17,631,489.00
- BCDA $3,000.00
- Revenue This Year
- CCTG N/A
- BCDA N/A
- Revenue Next Year
- CCTG N/A
- BCDA N/A
- P/E Ratio
- CCTG N/A
- BCDA N/A
- Revenue Growth
- CCTG 19.55
- BCDA N/A
- 52 Week Low
- CCTG $0.99
- BCDA $1.63
- 52 Week High
- CCTG $3.17
- BCDA $4.66
- Technical
- Relative Strength Index (RSI)
- CCTG 54.33
- BCDA 52.98
- Support Level
- CCTG $1.00
- BCDA $2.20
- Resistance Level
- CCTG $1.13
- BCDA $2.34
- Average True Range (ATR)
- CCTG 0.06
- BCDA 0.13
- MACD
- CCTG 0.01
- BCDA 0.01
- Stochastic Oscillator
- CCTG 85.71
- BCDA 65.56
About CCTG CCSC Technology International Holdings Limited
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas and Asia.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).